Oral News and Research

RSS
Researchers uncover unique cellular, molecular mechanisms behind tooth renewal

Researchers uncover unique cellular, molecular mechanisms behind tooth renewal

New nimodipine oral solution receives FDA approval for subarachnoid hemorrhage treatment

New nimodipine oral solution receives FDA approval for subarachnoid hemorrhage treatment

Misaligned teeth are chief culprits in the development of gum disease, tooth decay

Misaligned teeth are chief culprits in the development of gum disease, tooth decay

Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

Research findings may pave way to new treatment for Alzheimer's disease in humans

Research findings may pave way to new treatment for Alzheimer's disease in humans

Roundup: NYC examines solitary confinement alternatives for mentally ill inmates; Texas lawmakers push to modernize medical practices; N.C. cancer parity bill passes House

Roundup: NYC examines solitary confinement alternatives for mentally ill inmates; Texas lawmakers push to modernize medical practices; N.C. cancer parity bill passes House

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

New study provides clear picture of the impact and causes of diarrheal diseases

New study provides clear picture of the impact and causes of diarrheal diseases

TriStar Wellness Solutions completes acquisition of HemCon Medical Technologies

TriStar Wellness Solutions completes acquisition of HemCon Medical Technologies

Highlights: Feds sue Fla. Senate president's former company over Medicare billing practices; Okla. eyes existing Medicaid program to cover more people

Highlights: Feds sue Fla. Senate president's former company over Medicare billing practices; Okla. eyes existing Medicaid program to cover more people

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

New test determines which children with malaria are likely to develop cerebral malaria

New test determines which children with malaria are likely to develop cerebral malaria

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Affordable Care Act falls well short in improving health outcomes, reveals new ADA analysis

Affordable Care Act falls well short in improving health outcomes, reveals new ADA analysis

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Strax Rejuvenation reaches impressive milestone

Strax Rejuvenation reaches impressive milestone

PCORI awards $2M to UNC med school for diabetes research

PCORI awards $2M to UNC med school for diabetes research

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.